NuChem Sciences’ Carrageenan Model
NuChem Sciences’ carrageenan pain model stands as an ideal model in the study of inflammation and associated inflammatory pain. Central to its mechanism is the involvement of multiple Toll-Like Receptor (TLR) mediated local responses, underscoring its significance in understanding intricate molecular pathways. The model’s profound sensitivity to these pathways earmarks it as especially well-suited for the evaluation of local inflammatory drug targets.
The induction procedure is characterized by the injection of λ carrageenan solution into the mouse’s paw. Subsequent to this, the focus shifts to quantifying the resultant paw swelling or edema, a tangible manifestation of the inflammatory response. For utmost precision, measurements are ascertained using either a Plethysmometer or Caliper, ensuring both reliability and reproducibility.
When delineating our standard study design, it typically spans 4-6 distinct groups, with each group comprising 8-10 subjects. This structuring is geared towards capturing comprehensive data while maintaining statistical rigor. Notably, nonsteroidal anti-inflammatory drugs (NSAIDs) like Diclofenac have been tested as positive controls, fortifying the model’s relevance and credibility. As with our other models, the C57BL6 mouse species remains our validated choice, ensuring consistent and reproducible outcomes.
Following extensive evaluations within the carrageenan pain model, a concentration of 1% Carrageenan has been discerningly chosen as the optimal threshold. This meticulous selection was predicated on striking an ideal balance: ensuring a consistent and measurable inflammatory response while upholding the overarching principles of scientific integrity and animal well-being.
Furthermore, our investigative endeavors have underscored the profound efficacy of the nonsteroidal anti-inflammatory drug (NSAID) Diclofenac in this model. Administered within the framework of the model, Diclofenac markedly inhibited the characteristic paw swelling, showcasing its potent anti-inflammatory action. This significant attenuation of the inflammatory response by Diclofenac provides empirical validation for the model’s sensitivity and relevance.
In summation, the parameters finely honed in our carrageenan pain model, from the carefully calibrated Carrageenan concentration to the demonstrable effects of Diclofenac, epitomize NuChem Sciences’ dedication to rigorous, relevant, and revealing scientific inquiry.
< in vivo Pharmacology